{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 1a\/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1a-1b-study-of-27t51-an-anti-muc16-car-t-cell-drug-product-administered-alone-or-in-combination-for-participants-with-recurrent-or-refractory-epithelial-ovarian-primary-peritoneal-or-fallop\/#breadcrumbitem"}]}